Amjad Hijazi

Amjad Hijazi

Auto-generated profile, based on publicly available information

Amjad Hijazi

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Cancer Medicine
Verified
Journal Article
Open access
ZHZein Alabdin Hannouneh
Zein Alabdin Hannouneh
AHAmjad Hijazi
Amjad Hijazi
AAAlaa Aldeen Alsaleem
Alaa Aldeen Alsaleem
SHSiwan Hami
Siwan Hami
NKNina Kheyrbek
Nina Kheyrbek
ZAZuheir Alshehabi
Zuheir Alshehabi
Background: High‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC) presents a challenge to many physicians due to its ability to resist Bacillus Calmette–Guérin (BCG) intravesical therapy and the substantial rate of progression into muscle‐invasive bladder cancer (MIBC). Patients who are BCG‐unresponsive have worse prognosis and thus require further management including radical cystectomy (RC), which significantly impacts quality of life. Moreover, the ongoing worldwide shortage of BCG warrants the need for policies that prioritize drug use and utilize alternative treatment strategies. Hence, there is a significant unmet need for bladder preserving therapy in this subset of patients.Methods: To address this issue, we searched the relevant literature in PUBMED for articles published from 2019 through May of 2023 using appropriate keywords. All clinical trials of patients with HR‐NMIBC treated with immune‐related agents were retrieved from clinicaltrials.gov.Findings and Future Perspectives: Exploratory treatments for BCG‐Unresponsive HR‐NMIBC included immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators targeting TLR, EpCaM, FGFR, MetAP2, and IDO1. Some combination therapies have been found to work synergistically and are preferred therapeutically over monotherapy. Three drugs—pembrolizumab, valrubicin, and most recently, nadofaragene firadenovec‐vncg—have been FDA approved for the treatment of BCG‐unresponsive NMIBC in patients who are ineligible for or decline RC. However, all explored treatment options tend to postpone RC rather than provide long‐term disease control. Additional combination strategies need to be studied to enhance the effects of immunotherapy. Despite the challenges faced in finding effective therapies, many potential treatments are currently under investigation. Addressing the landscape of biomarkers, mechanisms of progression, BCG resistance, and trial design challenges in HR‐NMIBC is essential for the discovery of new targets and the development of effective treatments.

13 March 2026 in Cancer Letters
Verified
Journal Article
Closed access
SPSantiago Panesso-Gómez
Santiago Panesso-Gómez
ACAlexander J. Cole
Alexander J. Cole
AAAustin Arrigo
Austin Arrigo
ARAlex Roberts
Alex Roberts
MBMaya Bello
Maya Bello
Ronald BuckanovichRonald Buckanovich
Ronald Buckanovich

1 March 2011 in International Journal of Cardiology
Verified
Journal Article
Closed access
AHA. Hijazi
A. Hijazi
EEE. Erol
E. Erol
HCHulya Cicekcioglu
Hulya Cicekcioglu
OUO. Ucar
O. Ucar
VBV. Basar
V. Basar
ZCZ. Catav
Z. Catav